More than 135 million American adults are either living with or at risk for type 2 diabetes (T2D), elevating the need for ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...

RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use TETRANITE® to ...

The initiation of patient enrolment in the STARS DAPT trial marks an important milestone for Abluminus np. While contemporary ...

Vielight Neuro RX Gamma device and irradiation configuration used in the randomized, double-blind, sham-controlled trial.

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary ...

Any striking marketing claims in companies’ ads about the gut benefits of a popular probiotic may be full of, well, the same thing that has their target audience backed up. The study adds to a mixed ...

The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 ...

Trachoma is the leading cause of infectious blindness in the world, with Ethiopia the most impacted country in Africa. In a clinical trial of more than 2,400 individuals, researchers led by Dr. John ...